The valuation part of the presentation seemed surprising to the low side... A comparative antibiotic - not an anti infective mind you, but still - went through phase 3 and struck a deal worth $150m up front bullet with various bullet payments of $25m for sales targets reached. If that was all we could expect, it would be hard to justify a valuation much above the $25m usd floated in the case study... I was always expecting a larger chunk to be retained by recce.... I thought that was weird and underwhelming and confusing... Noting that recce has production capability, how should one think about the 'tax' paid in distribution and sales networks and a reasonable way to think about valuation?
- Forums
- ASX - By Stock
- Ann: Anti-Infective Portfolio Update and Webinar details
The valuation part of the presentation seemed surprising to the...
Featured News
Add RCE (ASX) to my watchlist
|
|||||
Last
54.5¢ |
Change
-0.030(5.22%) |
Mkt cap ! $111.1M |
Open | High | Low | Value | Volume |
58.0¢ | 58.0¢ | 54.5¢ | $73.79K | 132.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 3250 | 54.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
54.5¢ | 6587 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1250 | 0.540 |
1 | 50000 | 0.510 |
6 | 70000 | 0.500 |
1 | 50000 | 0.495 |
1 | 5000 | 0.490 |
Price($) | Vol. | No. |
---|---|---|
0.545 | 6587 | 1 |
0.560 | 1310 | 1 |
0.565 | 26178 | 1 |
0.570 | 49979 | 1 |
0.580 | 8333 | 1 |
Last trade - 16.10pm 24/06/2024 (20 minute delay) ? |
Featured News
RCE (ASX) Chart |